Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
- Arrowhead Earns $15 million Milestone from Horizon Therapeutics plc PASADENA, Calif. --(BUSINESS WIRE)--Dec. 8, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Horizon Therapeutics plc (Nasdaq: HZNP) has enrolled the first subject, earning Arrowhead a $15 million
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
- Conference Call and Webcast Today, November 28, 2022 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 28, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2022 . The company is hosting a conference call today,
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 21, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Piper Sandler 34 th Annual Healthcare Conference – November 30, 2022 Type: Fireside chat presentation
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
PASADENA, Calif. --(BUSINESS WIRE)--Nov. 14, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 28, 2022 , at 4:30 p.m. ET to discuss its financial results for the 2022 fiscal year ended September 30, 2022 .
View HTML
Toggle Summary Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
- Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease - Arrowhead retains rights to $400 million in development, regulatory, and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement PASADENA, Calif.
View HTML
Toggle Summary Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
- ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia - ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 13, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 4, 2022 , the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
- Company will host a virtual analyst and investor event on November 9, 2022 PASADENA, Calif. --(BUSINESS WIRE)--Oct. 11, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 1, 2022-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022 Title: Silencing MMP7
View HTML
Toggle Summary Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 17, 2022-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce
View HTML